Biomarkers to Predict Cancer Therapy-related Cardiotoxicity

Mayo Clinic

Status

Enrolling

Conditions

Hematopoietic and Lymphatic System Neoplasm

Malignant Solid Neoplasm

Treatments

Other: Non-Interventional Study

Study type

Observational

Funder types

Other

NIH

Identifiers

NCT06353191

19-002566 (Other Identifier)

NCI-2024-00943 (Registry Identifier)

R01HL169268 (U.S. NIH Grant/Contract)

R56HL160643 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

This study evaluates why some cancer patients but not others experience changes in heart function following treatment with chemotherapy.

Full description

PRIMARY OBJECTIVE:

I. To collect biospecimens from 1) patients who developed chemotherapy related cardiac toxicity (CRCT) and 2) patients who are at a high risk for developing CRCT.

OUTLINE: This is an observational study.

Patients undergo blood sample collection and have their medical records reviewed on study.

Enrollment

1,000 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

18 years of age or older
Treated for any malignancy with any type of chemotherapy including oral, parenteral therapy and immunotherapy
One of the following:
- Diagnosed with cardiotoxicity defined as; cardiomyopathy, symptomatic heart failure, asymptomatic reduced systolic function, acute coronary syndrome, myocardial infarction, critical limb ischemia, cardiac arrhythmias or myocarditis possibly related to prior cancer treatment
- Completed chemotherapy with no cardiotoxicity at least two years post treatment
- Patients with cancer who will be initiating systemic therapy with potentially cardiotoxic medications. This will include chemotherapy, immunotherapy, targeted therapy that have been associated with cardiac toxicity
An understanding of the protocol and its requirements, risks, and discomforts
The ability and willingness to sign an informed consent